YD Bio (YDES) Enterprise Value (2024 - 2025)
YD Bio (YDES) posted quarterly Enterprise Value of -$6.0 million for Q4 2025, down 91.8% year-over-year from -$73.2 million in Q4 2024, and down 1179.52% quarter-over-quarter from -$469520.0 in Q2 2025.
YD Bio (YDES) Enterprise Value (2024 - 2025) Analysis & Trends
YD Bio (YDES) has reported Enterprise Value for 2 consecutive years, with -$6.0 million the latest figure, recorded in Q4 2025.
- In Q4 2025, Enterprise Value fell 91.8% year-over-year to -$6.0 million; the TTM figure through Dec 2025 stood at -$6.0 million (down 91.8% YoY), while the FY2025 annual figure was -$6.0 million, down 91.8% from the prior year.
- Enterprise Value retreated to -$6.0 million in Q4 2025 per YDES's latest filing, from -$469520.0 in the prior quarter.
- Across five years, Enterprise Value topped out at -$469520.0 in Q2 2025 and bottomed at -$6.0 million in Q4 2025.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Enterprise Value (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 139.29 Bn | 131.44 Bn | 2.84 Bn | -7.85 Bn |
| 2 | Regeneron Pharmaceuticals | 86.31 Bn | 78.32 Bn | 3.93 Bn | -7.99 Bn |
| 3 | Argenx Se | 65.22 Bn | 60.03 Bn | 1.37 Bn | -5.18 Bn |
| 4 | Moderna | 58.92 Bn | 53.78 Bn | 52.00 Mn | -5.14 Bn |
| 5 | BeOne Medicines | 42.07 Bn | 36.97 Bn | 1.53 Bn | -5.10 Bn |
| 6 | Alnylam Pharmaceuticals | 31.70 Bn | 28.39 Bn | 992.69 Mn | -3.31 Bn |
| 7 | BioNTech SE | 27.99 Bn | 9.60 Bn | 668.28 Mn | -18.39 Bn |
| 8 | Insmed | 27.51 Bn | 26.35 Bn | 358.27 Mn | -1.16 Bn |
| 9 | Royalty Pharma | 27.28 Bn | 26.45 Bn | - | 2.12 Bn |
| 10 | YD Bio | 317.58 Mn | 311.58 Mn | - | -6.01 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Dec 31, 2025 | -6.01 Mn |
| Jun 30, 2025 | -469,520.00 |
| Dec 31, 2024 | -3.13 Mn |